peripheral T-cell lymphoma, not otherwise specified
peripheral T-cell lymphoma, not otherwise specified
Explore linked clinical trials. Standard reference: MONDO:000496410 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 2 | 2026-10-02 | NCT04803201 | |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 3 | 2026-09-25 | NCT06561048 | |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | ALK-negative anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 3 | 2026-09-14 | NCT06724237 | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Active, not recruiting | Phase 2 | 2026-08-21 | NCT03113500 | |
| Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 2 | 2026-08-05 | NCT07293403 | |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-07-01 | NCT06508463 | |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphadenopathy, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, diffuse large B-cell lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell non-Hodgkin lymphoma, primary cutaneous anaplastic large cell lymphoma, primary mediastinal large B-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma | Active, not recruiting | Not applicable | 2026-06-16 | NCT01787409 | |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 1 | 2026-06-05 | NCT07278856 | |
| A Registry for People With T-cell Lymphoma | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Leukemia, Large Granular Lymphocytic, Lymphadenopathy, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, breast implant-associated anaplastic large cell lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, hydroa vacciniforme-like lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monomorphic epitheliotropic intestinal T-cell lymphoma, mycosis fungoides, neoplasm, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma, primary cutaneous anaplastic large cell lymphoma, prolymphocytic leukemia, subcutaneous panniculitis-like T-cell lymphoma | Recruiting | Not stated | 2026-05-20 | NCT05978141 | |
| Q702 for the Treatment of Patients With Hematologic Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Erdheim-Chester disease, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, bone marrow disorder, cardiovascular disorder, chronic myelomonocytic leukemia, follicular lymphoma, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, histiocytic sarcoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, interstitial lung disease, leukemia, lung disorder, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, monoclonal gammopathy, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, non-Langerhans cell histiocytosis, peripheral T-cell lymphoma, not otherwise specified, plasma cell neoplasm, primary central nervous system lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, respiratory system disorder, skin disorder, skin neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2025-10-10 | NCT06712810 |